Related Experiment Videos
Gentamicin in the treatment of infections due to penicillinase-producing gonococci
The British Journal of Venereal Diseases
|December 1, 1980
Abstract:
Ninety-seven patients with infections due to penicillinase-producing Neisseria gonorrhoeae (PPNG) were treated with single doses of gentamicin 280 mg intramuscularly. The failure rate among those followed up was 3%. No significant side effects were recorded. Gentamicin is a valuable alternative in the treatment of infections due to PPNG strains.
Insights
Gentamicin effectively treated infections from penicillinase-producing Neisseria gonorrhoeae (PPNG) with a low failure rate. This study suggests gentamicin is a safe and valuable alternative for treating these specific gonorrhea strains.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Penicillinase-producing Neisseria gonorrhoeae (PPNG) presents a significant challenge in gonorrhea treatment.
- Antimicrobial resistance in Neisseria gonorrhoeae necessitates exploring alternative therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and safety of single-dose intramuscular gentamicin for treating infections caused by PPNG.
- To determine the failure rate and side effects associated with this treatment regimen.
Main Methods:
- A cohort of ninety-seven patients with PPNG infections received a single intramuscular dose of gentamicin (280 mg).
- Patient outcomes were monitored to assess treatment success and record any adverse events.
Main Results:
- A low failure rate of 3% was observed among patients followed up after treatment.
- No significant adverse side effects were reported during the study period.
Conclusions:
- Single-dose intramuscular gentamicin is an effective and well-tolerated treatment for infections caused by PPNG strains.
- Gentamicin represents a valuable therapeutic alternative for managing gonorrhea caused by resistant Neisseria gonorrhoeae.